Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 7, 2013, Pages 519-525

  Kang, Cheol In ^a   Wi, Yu Mi ^a   Ko, Kwan Soo ^a,b   Chung, Doo Ryeon ^a   Peck, Kyong Ran ^a   Lee, Nam Yong ^a   Song, Jae Hoon ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Asia Pacific Foundation for Infectious Diseases (APFID)   (South Korea)

Author keywords

Bacteremia; Cephalosporin resistance; Community acquired infections; Escherichia coli; Treatment outcome

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; CARBAPENEM DERIVATIVE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BILIARY TRACT INFECTION; CARDIOVASCULAR DISEASE; CENTRAL VENOUS CATHETERIZATION; COHORT ANALYSIS; COMMUNICABLE DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INDWELLING URINARY CATHETER; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SENESCENCE; SEPSIS; SEPTIC SHOCK; SOLID TUMOR; SURGICAL INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879077634     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.775479     Document Type: Article

References (26)

1. Cheong HS, K ang CI, K won KT, H eo ST, W i YM, K im ES, et al. Clinical signifi cance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60: 1355-60.
2. Ortega M, M arco F, S oriano A, A lmela M, M artinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibioticresistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63: 568-74.
3. Paterson DL, B onomo RA. E xtended-spectrum betalactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
4. Cheong HS, K o KS, K ang CI, C hung DR, P eck KR, Song JH. Prevalence of extended-spectrum beta-lactamase among Enterobacteriaceae blood isolates with inducible AmpC beta-lactamase. Infect Chemother 2010; 42: 280-4.
5. Arpin C, D ubois V, C oulange L, A ndre C, F ischer I, Noury P, et al. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-14.
6. K ang C I, K im SH, P ark WB, L ee KD, K im HB, K im EC, et al. Bloodstream infections due to extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
7. Azap O K, A rslan H, S erefhanoglu K, C olakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extendedspectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin MicrobioLinfect 2010; 16: 147-51.
8. Ben-Ami R, Rodriguez-Bano J, A rslan H, P itout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamaseproducing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-90.
9. Calbo E, R omani V, X ercavins M, G omez L, V idal C G, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extendedspectrum beta-lactamases. J Antimicrob Chemother 2006; 57: 780-3.
10. Kang C I, S ong J H, C hung D R, P eck K R, K o K S, Y eom J S, et al. Risk factors and treatment outcomes of communityonset bacteraemia caused by extended-spectrum betalactamase-producing Escherichia coli. Int J Antimicrob Agents 2010; 36: 284-7.
11. Pitout J D, H anson N D, C hurch D L, L aupland K B. P opulation-based laboratory surveillance for Escherichia coliproducing extended-spectrum beta-lactamases: importance of community isolates with bla CTX-M genes. Clin Infect Dis 2004; 38: 1736-41.
12. Pitout J D, N ordmann P, L aupland K B, P oirel L. E mergence of Enterobacteriaceae producing extended-spectrum betalactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-9.
13. A lcala J C, C isneros J M, G rill F, O liver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
14. Rodriguez-Bano J, P icon E, G ijon P, H ernandez J R, R uiz M, Pena C, et al. Community-onset bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50: 40-8.
15. Rodriguez-Bano J, N avarro M D, R omero L, M uniain M A, de Cueto M, Rios MJ, et al. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
16. Friedman ND, K aye KS, S tout JE, M cGarry SA, T rivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted defi nition of community-acquired infections. Ann Intern Med 2002; 137: 791-7.
17. Kang CI, K im SH, P ark WB, L ee KD, K im HB, K im EC, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760-6.
18. Kim J, Lim Y M, Jeong Y S, Seol S Y. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14, and CTX-M-9 extended-spectrum beta-lactamases in Enterobacteriaceae clinicaLisolates in Korea. Antimicrob Agents Chemother 2005; 49: 1572-5.
19. Kim J, Lim YM, R heem I, L ee Y, L ee JC, S eol SY, et al. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinicaLisolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. FEMS Microbiol Lett 2005; 245: 93-8.
20. S chwaber MJ, C armeli Y. M ortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
21. Tumbarello M, S panu T, S anguinetti M, C itton R, M ontuori E, Leone F, et al. Bloodstream infections caused by extendedspectrum-beta-lactamase- producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
22. Kang CI, C hung DR, K o KS, P eck KR, S ong JH. R isk factors for mortality and impact of broad-spectrum cephalosporin resistance on outcome in bacteraemic intraabdominaLinfections caused by Gram-negative bacilli. Scand J Infect Dis 2011; 43: 202-8.
23. Joo E J, K ang C I, H a Y E, P ark S Y, K ang S J, W i Y M, et a l. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratifi ed analysis according to sites of infection. Infection 2011; 39: 309-18.
24. Cheong H S, K ang C I, L ee J A, M oon SY, J oung M K, Chung DR, et al. Clinical signifi cance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 1230-6.
25. Rodriguez-Bano J, N avarro M D, R etamar P, P icon E, Pascual A. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-74.
26. Kang CI, P ark SY, C hung DR, P eck KR, S ong JH. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. J Infect 2012; 64: 533-4.